

LOS ANGELES POLICE COMMISSION

**BOARD OF
POLICE COMMISSIONERS**

WILLIAM J. BRIGGS, II
PRESIDENT

DR. ERROLL G. SOUTHERS
VICE PRESIDENT

MARIA LOU CALANCHE
RASHA GERES SHIELDS
STEVE SOBOROFF

MARIA SILVA
COMMISSION EXECUTIVE ASSISTANT II



KAREN BASS
MAYOR

RICHARD M. TEFANK
EXECUTIVE DIRECTOR

MARK P. SMITH
INSPECTOR GENERAL

EXECUTIVE OFFICE
POLICE ADMINISTRATION BUILDING
100 WEST FIRST STREET, SUITE 134
LOS ANGELES, CA 90012-4112

(213) 236-1400 PHONE
(213) 236-1410 FAX
(213) 236-1440 TDD

July 18, 2023

BPC #23-136

The Honorable Karen Bass
Mayor, City of Los Angeles
City Hall, Room 303
Los Angeles, CA 90012

The Honorable City Council
City of Los Angeles, Room 395
c/o City Clerk's Office

Dear Honorable Members:

RE: GRANT APPLICATION AND AWARD FOR THE CHP CANNABIS TAX FUND GRANT PROGRAM.

At the regular meeting of the Board of Police Commissioners held Tuesday, July 18, 2023, the Board APPROVED the Department's report relative to the above matter.

Respectfully,

BOARD OF POLICE COMMISSIONERS

A handwritten signature in blue ink that reads "Rebecca Munoz".

REBECCA MUNOZ
Commission Executive Assistant

Attachment

c: Chief of Police

INTRADEPARTMENTAL CORRESPONDENCE

Richard M. Tefank
RICHARD M. TEFANK
EXECUTIVE DIRECTOR
DATE 7/12/23
23-136

July 12, 2023
1.14

TO: The Honorable Board of Police Commissioners

FROM: Chief of Police

SUBJECT: TRANSMITTAL OF THE GRANT APPLICATION AND AWARD
ACCEPTANCE FOR THE 2023/2025 CHP CANNABIS TAX FUND
GRANT PROGRAM – TOXICOLOGY LABORATORY

RECOMMENDED ACTIONS

1. That the Board of Police Commissioners (Board) REVIEW and APPROVE this report.
2. That the Board TRANSMIT the attached grant application and award for the Fiscal Year (FY) 2023/2025 Cannabis Tax Fund Grant Program – Toxicology Laboratory pursuant to Administrative Code Section 14.6(a), to the Mayor, Office of the City Administrative Officer (CAO), Chief Legislative Analyst, and to the City Clerk for committee and City Council consideration.
3. That the Board REQUEST the Mayor and City Council to:
 - A. AUTHORIZE the Chief of Police or his designee to retroactively apply for and ACCEPT the FY 2023/2025 Cannabis Tax Fund Grant Program – Toxicology Laboratory award in the amount of \$700,000 from the State of California, Department of California Highway Patrol (CHP) for the period of July 1, 2023 through June 30, 2025;
 - B. AUTHORIZE the Chief of Police or his designee to execute an Award Agreement with CHP, subject to the City Attorney’s approval as to form;
 - C. AUTHORIZE the Los Angeles Police Department (LAPD) to spend up to \$700,000 in accordance with the grant award agreement;
 - D. AUTHORIZE the Controller to set up a grant receivable and appropriate \$700,000 to appropriation account number to be determined in Fund No. 339, Department No. 70, for the disbursement of the FY 2023/2025 Cannabis Tax Fund Grant Program – Toxicology Laboratory funds;
 - E. AUTHORIZE the LAPD to submit grant reimbursement requests to the grantor and deposit grant receipts in Fund No. 339, Department No. 70; and,

- F. AUTHORIZE the LAPD to prepare the Controller instructions for any technical adjustments, subject to the approval of the CAO, and INSTRUCT the Controller to implement the instructions.

DISCUSSION

The CHP Cannabis Tax Fund Grant Program provides education, prevention, and enforcement of impaired driving laws related to driving under the influence of alcohol and other drugs, including cannabis. For FY 2023/2025, the CHP extended the funding opportunity to toxicology laboratories to improve and advance the standardization of practices in toxicology laboratories supporting and aiding in the enforcement of Driving Under the Influence (DUI)/Driving Under the Influence of Drugs (DUID) traffic laws related to alcohol and other drugs, including cannabis and cannabis products.

The Forensic Science Division was awarded \$700,000 to aid CHP in its efforts. The goal is for the LAPD Toxicology Unit to (1) be fully compliant with the standards for confirmatory testing of DUID blood specimens; (2) include the top five most prevalent fentanyl analogues in the DUID confirmatory testing scope; (3) reduce the amount of blood specimen used for narcotic analgesic confirmations; and, (4) eliminate the need for subcontracted testing to meet standards for confirmatory testing for narcotic analgesics.

Funds will be used for overtime to validate the new narcotic analgesic confirmation method within the grant performance period. Funds will also be used to purchase one new Liquid Chromatograph with Tandem Mass Spectrometers. It offers exceptional sensitivity, resolving power, accurate mass determination, and targeted drug detection. It will increase the Toxicology Unit's ability to meet its' goals and ensure investigators receive accurate and comprehensive laboratory results, ultimately improving driving safety within the City of Los Angeles.

If you have any questions regarding this transmittal, please contact Senior Management Analyst Stella Larracas, Officer in Charge, Grants Section, at (213) 486-0380.

Respectfully,



MICHEL R. MOORE
Chief of Police

**BOARD OF
POLICE COMMISSIONERS**

Approved *July 18, 2023*
Secretary *Rebecca Mung*

Attachments

INTRADEPARTMENTAL CORRESPONDENCE

July 11, 2023

1.14

TO: Chief of Police

FROM: Director, Office of Constitutional Policing and Policy

SUBJECT: TRANSMITTAL OF THE GRANT APPLICATION AND AWARD
ACCEPTANCE FOR THE 2023/2025 CHP CANNABIS TAX FUND
GRANT PROGRAM – TOXICOLOGY LABORATORY

Attached for your approval and signature is an Intradepartmental Correspondence to the Board of Police Commissioners, requesting approval to transmit the attached Grant Application and Award for the Fiscal Year (FY) 2023/2025 Cannabis Tax Fund Grant Program – Toxicology Laboratory, pursuant to Administrative Code Section 14.6(a), to the Mayor, Office of the City Administrative Officer, Office of the Chief Legislative Analyst, City Clerk for Committee, and City Council consideration. The Los Angeles Police Department (LAPD) is requesting authorization to accept the grant funding in the amount of \$700,000 from the State of California for the period of July 1, 2023 through June 30, 2025.

The Forensic Science Division was awarded \$700,000 to improve and advance the standardization of practices in toxicology laboratories supporting and aiding in the enforcement of Driving Under the Influence (DUI)/Driving Under the Influence of Drugs (DUID) traffic laws related to alcohol and other drugs, including cannabis and cannabis products.

The LAPD Toxicology Unit goal is to (1) be fully compliant with the standards for confirmatory testing of DUID blood specimens; (2) include the top five most prevalent fentanyl analogues in the DUID confirmatory testing scope; (3) reduce the amount of blood specimen used for narcotic analgesic confirmations; and, (4) eliminate the need for subcontracted testing to meet standards for confirmatory testing for narcotic analgesics.

Funds will be used for overtime to validate the new narcotic analgesic confirmation method within the grant performance period, and to purchase one new Liquid Chromatograph with Tandem Mass Spectrometers. It offers exceptional sensitivity, resolving power, accurate mass determination, and targeted drug detection. It will increase the Toxicology Unit's ability to meet its' goals and ensure investigators receive accurate and comprehensive laboratory results, ultimately improving driving safety within the City of Los Angeles.

If you have any questions, please contact Senior Management Analyst Stella Larracas, Officer in Charge, Grants Section, at (213) 486-0380.



LIZABETH RHODES, Director
Office of Constitutional Policing and Policy

Attachments

DEPARTMENT OF CALIFORNIA HIGHWAY PATROL

601 North 7th Street
Sacramento, CA 95811
(916) 843-3330
(800) 735-2929 (TT/TDD)
(800) 735-2922 (Voice)



June 7, 2023

File No.: 060.15426.14597.066.2023.06004

Barbra Montesquieu
Los Angeles Police Department
100 West First Street, Suite 1061
Los Angeles, CA 90012

Dear Ms. Montesquieu:

On behalf of the California Highway Patrol (CHP), it is my pleasure to inform you, the Los Angeles Police Department, is conditionally approved for Cannabis Tax Fund Grant Program (CTFGP) funding for the Toxicology Grant Opportunity in the amount of \$700,000.00. The purpose of this grant funding is to help your agency reduce and mitigate the impacts of impaired driving in your community.

The official Grant Agreement for signature is forthcoming. In order to execute your Grant Agreement, please provide documentation from a local governing body, authorizing your organization to receive this grant funding, to the Cannabis Grants Unit, by email at CGUGrants@chp.ca.gov, as soon as possible. Refer to California Code of Regulations Title 13, Division 2, Chapter 13, Section 1890.13(g) for additional information.

The CHP looks forward to partnering with you and your agency on this project in an effort to make California's roadways a safer place to travel. If you have any questions, please feel free to contact the Cannabis Grants Unit at (916) 843-4360.

Sincerely,

A handwritten signature in blue ink that reads "K. M. Davis".

K. M. DAVIS, Chief
Enforcement and Planning Division





City of Los Angeles - Los Angeles Police Department

Prepared by Los Angeles Police Department
for California Highway Patrol (CHP) Toxicology: Crime Laboratories FY 2023/2025

Submitted by Barbra Montesquieu

Submitted on 02/23/2023 8:13 AM Pacific Standard Time



Opportunity Details

Opportunity Information

Title

Toxicology: Crime Laboratories FY 2023/2025

Description

Toxicology: Crime Laboratory grants shall be in direct support of grant-funded Project activities that aide in the enforcement of laws related to driving under the influence of alcohol and other drugs (DUVDUID), including cannabis and cannabis products.

Awarding Agency Name

California Highway Patrol

Agency Contact Name

Cannabis Grants Unit (CGU)

Agency Contact Phone

916-843-4360

Agency Contact Email

CGUGrants@chp.ca.gov

Fund Activity Categories

Science and Technology and Other Research and Development

Departments

Subjects

Opportunity Manager

Cannabis Grants Unit (CGU)

Opportunity Posted Date

1/6/2023

Public Link

<https://www.gotomygrants.com/Public/Opportunities/Details/0c208fce-b109-43dc-bf00-55098805133f>

Is Published

Yes

Funding Information

Funding Sources

State

Funding Source Description

With the passage of Proposition 64 in 2016, The Control, Regulate, and Tax Adult Use Marijuana Act (AUMU), California voters mandated the state to set aside funding for the CHP to provide grants to local governments and qualified non-profit organizations for the education, prevention, and enforcement of impaired driving laws pursuant to Section 34019 (f)(3)(B) Revenue and Taxation Code (RTC).

Funding Restrictions

State Agencies/Departments, please refer to Section 34019 (f)(3)(b) RTC and California Code of Regulations, Title 13, Division 2, Chapter 12, for additional information.



Award Information

Award Range
\$2,000,000.00 Ceiling

Award Period
07/01/2023 - 06/30/2025

Award Type
Competitive

Indirect Costs Allowed
No

Matching Requirement
No

Submission Information

Submission Window
01/06/2023 8:00 AM - 02/23/2023 5:00 PM

Submission Timeline Type
One Time

Submission Timeline Additional Information

Grant Applicants are advised to ask submittal questions well before the deadline. The Cannabis Grants Unit cannot guarantee an immediate response and the Grant Management System (GMS) will automatically close at 5:00 PM PST. Once a Grant Application is submitted through the GMS, Grant Applicants may not add, edit, or delete any Grant Application information.

Question Submission Information

Question Submission Email Address
CGUGrants@chp.ca.gov

Eligibility Information

Eligibility Type
Public

Additional Eligibility Information
Local Government, which includes California County and/or City Crime Laboratories

Additional Information

Additional Information URL
<https://www.chp.ca.gov/programs-services/programs/cannabis-tax-fund-grant-program>

Award Administration Information

State Award Notices
Awards will be announced in May and June 2023.

Administrative and National Policy Requirements
The California Highway Patrol (CHP) adopted regulations within Title 13 of the California Code of Regulations (CCR), Division 2, by adding Chapter 13, which govern the CHP Cannabis Tax Fund Grant Program.



These regulations outline:

- * Grant Provisions
- * Grant Project Types
- * Specific Grant Application Requirements
- * Grant Evaluation Criteria
- * Necessary Administrative Procedures for the Program.

Regulations can be found at:

<https://www.chp.ca.gov/programs-services/programs/cannabis-tax-fund-grant-program/program-regulations>

Reporting

Quarterly Reporting is required and due within 14 calendar days after the close of each quarter.

FY 2023/2024

Year One, Quarter One (Y1 Q1): July 1 - September 30

Year One, Quarter Two (Y1 Q2): October 1 - December 31

Year One, Quarter Three (Y1 Q3): January 1 - March 31

Year One, Quarter Four (Y1 Q4): April 1 - June 30

FY 2024/2025

Year Two, Quarter One (Y2 Q1): July 1 - September 30

Year Two, Quarter Two (Y2 Q2): October 1 - December 31

Year Two, Quarter Three (Y2 Q3): January 1 - March 31

Year Two, Quarter Four (Y2 Q4): April 1 - June 30

Other Information

Please ensure your Organization/Agency has the capability to electronically sign required documents (ex: Grant Agreement).



Project Information

Application Information

Application Name

City of Los Angeles - Los Angeles Police Department

Award Requested

\$700,000.00

Total Award Budget

\$700,000.00

Primary Contact Information

Name

Barbra Montesquieu

Email Address

n3202@lapd.online

Address

100 West First Street, Suite 1061
Los Angeles, CA 90012

Phone Number

(210) 486-0380



Project Description

1. Organization/Agency Representatives

Organization/Agency Section/Unit (subdivision) to administer the Grant Agreement

Los Angeles Police Department

Organization/Agency Representative

Please complete the following fields with appropriate Agency representatives, as applicable.

- The Authorized Official is authorized to enter into a Grant Agreement with signing authority.
- The Authorized Financial Contact maintains financial records, documentation, and recipient of warrant.
- The Administrative Contact is responsible for day-to-day administration.

Note: Information requested is for Grant Application purposes only. Security roles (titles) differ from those within the GMS.

Authorized Official Name (first and last)

Michel R. Moore

Authorized Official Title

Chief of Police

Authorized Official Address (street, city, state, zip code)

100 West First St, Los Angeles CA 90012

Official Address to Receive Reimbursement Payment - MUST MATCH FISCAL FORM (street, city, state, zip code)

LAPD, Fiscal Group, 100 W 1st St, Rm 774 Attn: Grants, LA CA 90030

Authorized Official Phone Number (with area code)

213-486-0150

Authorized Official Email Address

grants@lapd.online

Authorized Financial Contact Name (first and last)

Ms. Stella Larracas

Authorized Financial Contact Title

Sr. Management Analyst II

Authorized Financial Contact Phone Number (with area code)

213-486-0380

Authorized Financial Contact Email Address

N3371@lapd.online

Administrative Contact Name (first and last)

Barbra Montesquieu

Administrative Contact Title

Sr. Management Analyst

Administrative Contact Phone Number (with area code)

213-486-0380

Administrative Contact Email Address



n3202@lapd.online



2. Senate/Assembly/Congressional/County Information

Instructions

To determine the State Senate District(s), State Assembly District(s), and California Congressional District(s), copy and paste the below URL in your browser and search:

<https://gis.data.ca.gov/maps/CDEGIS::legislative-districts-in-california-2/about>
<https://gis.data.ca.gov/maps/CDEGIS::legislative-districts-in-california-2/about>

Select one or more State Senate District(s) where the proposed Project activities will occur. To make multiple selections, hold down the Ctrl key and click each one.

State Senate 18, State Senate 24, State Senate 25, State Senate 26, State Senate 27, State Senate 30, State Senate 33, State Senate 35

Select one or more State Assembly District(s) where the proposed Project activities will occur. To make multiple selections, hold down the Ctrl key and click each one.

State Assembly 38, State Assembly 39, State Assembly 43, State Assembly 45, State Assembly 46, State Assembly 50, State Assembly 51, State Assembly 53, State Assembly 54, State Assembly 59, State Assembly 62, State Assembly 64, State Assembly 66, State Assembly 70

Select one or more California Congressional District(s) where the proposed Project activities will occur. To make multiple selections, hold down the Ctrl key and click each one.

California Congressional District 25, California Congressional District 28, California Congressional District 29, California Congressional District 30, California Congressional District 33, California Congressional District 34, California Congressional District 37, California Congressional District 40, California Congressional District 43, California Congressional District 44

Select one or more California counties where the proposed Project activities will occur. To make multiple selections, hold down the Ctrl key and click each one.

Los Angeles

Number of residents (population) that your Organization/Agency serves.

3849000



3. Statistical Data

Please ensure the responses below are accurate and align with the statistical data provided within the Grant Application.

If a question is not applicable, please input "0" or "N/A".

Approximately how many qualified analysts are conducting Driving Under the Influence (DUI)/Driving Under the Influence of Drugs (DUID) testing at your laboratory?*

	Monthly Average	Yearly Average
Approximate Number of Analysts	12	12

Approximately how many DUID cases does your laboratory analyze for drugs only?*

	Monthly Average	Yearly Average
Approximate Number of Cases	70	850

Approximately how many DUI cases does your laboratory analyze for alcohol only?*

	Monthly Average	Yearly Average
Approximate Number of Cases	66	794

Approximately how many cases are tested for both alcohol and drugs?*

	Monthly Average	Yearly Average
Approximate Number of Cases	21	260

What is the estimated turn-around time for case analysis?*

	DUI Cases	DUID Cases	DUI/DUID Cases
Estimated Number of Days	3	42	50

What is the estimated number of backlogged DUI cases?*

	Monthly Average	Yearly Average
Estimated Number of Cases	0	0

Approximately how many times per year does your laboratory provide DUI/DUID-related court testimony?*

	DUI Cases	DUID Cases	DUI/DUID Cases
Approximate Number of Times Per Year	60	17	n/a

Does your Organization/Agency track which samples have an associated Drug Recognition Expert (DRE) evaluation?

- Yes
- No

If yes, what is the percentage?

Does your laboratory make an administrative decision to stop testing if a blood alcohol concentration (BAC) result is at or above a specific BAC?

- Yes



No

If yes, what is that BAC concentration result?

When a customer requests "alcohol only" testing, the blood specimen is only screened for drugs when the blood alcohol result is less than or equal to 0.08 g%. When a customer requests "drugs and alcohol" testing, the testing is NOT stopped regardless of blood alcohol concentration.

Please list the top 10 drugs present in your laboratory's current DUID case work (number 1-10; 1 = most prevalent). If unknown or not tracked, please provide any known information.

1. Cannabis (THC/THCCOOH)
2. Methamphetamine/Amphetamine
3. Cocaine (Cocaine/Benzoyllecgonine/Cocaethylene)
4. Fentanyl
5. Alprazolam
6. PCP
7. Oxycodone
8. Carisoprodol/Meprobamate
9. Diazepam (Nordiazepam)/Clonazepam
10. Methadone

Grant Funded Equipment

Have Cannabis Tax Fund Grant Program Grant Funds been utilized to purchase equipment (an acquisition cost of at least \$5,000)?

- Yes
 No

If yes, list EACH equipment item and fiscal year of the Grant Agreement.

- (1) Thermo Altis Quadrupole with Vanquish Liquid Chromatograph (LC/MS/MS)
 - a. Funded by CHP Cannabis Tax Fund Grant FY 2021-2022
 - b. Instrument purchased, installed, and currently in use
- (2) Thermo Orbitrap Exploris 120 with Vanquish Liquid Chromatograph
 - a. Funded by CHP Cannabis Tax Fund Grant FY 2022-2023
 - b. Purchase in progress with anticipated installation by July 2023

Current Equipment

What equipment does your laboratory use (make/model)? How many of each?

Drug Screening



Tecan Freedom EVO 75 (Quantity 2)

Beckman Coulter AU480 (Quantity 1)

Drug Confirmation Testing

Sciex 3200 Triple Quadrupole with Agilent 1200 Series Liquid Chromatograph (LC/MS/MS) (Quantity 1)

Sciex 5500+ Triple Quadrupole with ExionLC Liquid Chromatograph (LC/MS/MS) (Quantity 1)

Thermo Altis Quadrupole with Vanquish Liquid Chromatograph (LC/MS/MS) (Quantity 1)

Hewlett Packard Gas Chromatograph 6890 with Mass Spectrometer 5973 (GC/MS) (Quantity 1)

Agilent Technologies Gas Chromatograph 7890A with Mass Spectrometer 5975C (GC/MS) (Quantity 2)

Agilent Technologies Gas Chromatograph 7890B with Mass Spectrometer 5977B (GC/MS) (Quantity 2)

Agilent Technologies Gas Chromatograph 6890N with Mass Spectrometer 5975 (GC/MS) (Quantity 1)

Alcohol Analysis

Shimadzu GC-2010 Gas Chromatograph with Flame-Ionization Detector (Quantity 2)

What equipment is currently needed? Please detail the need for the equipment.

The Los Angeles Police Department (LAPD) Forensic Science Division (FSD) Toxicology (TOX) Unit needs a new generation ultra-high-performance liquid chromatograph with tandem mass spectrometers (LC/MS/MS) with the sensitivity requirements to fully meet NSC Tier 1 drug testing recommendations. With the technology of the new LC/MS/MS, the TOX Unit will develop a comprehensive narcotic analgesic confirmation panel for DUID-related blood specimens that meet the NSC and ASB published standards and will be able to confirm the top five relevant fentanyl analogs. The TOX Unit does not currently have the equipment with sufficient sensitivity and specificity necessary to develop the comprehensive narcotic analgesic confirmation panel.

If equipment is needed, will it be able to test for Delta-9-Tetrahydrocannabinol(THC), 11-Hydroxy-THC and Carboxy-THC?

- Yes
- No

If new equipment is purchased, is staff training needed?

- Yes
- No

If yes, please detail what training is needed?



4. Project Description

Provide a brief overview/synopsis (a paragraph) of the proposed Project, detailing what activities/items will be used to obtain the desired outcome(s). PLEASE DO NOT COPY AND PASTE TABLES IN FIELD - TYPE INFORMATION IN FIELD.

The LAPD TOX Unit receives approximately 1,200 DUID-related blood specimens each year for testing. The drug testing process for these specimens involves two steps: first, blood specimens are **screened** for numerous drug classes; and second, positive drug screening results are **confirmed** by a second analytical technique utilizing mass spectrometry. The NSC Alcohol, Drug, and Impairment Division has published minimum recommendations for screening and confirmatory testing for Tier 1 drugs, including a scope of target drugs, and sensitivity requirements.

The TOX Unit is in the process of purchasing a liquid chromatograph with a high-resolution mass spectrometer (Thermo Scientific Orbitrap Exploris 120), using CHP Cannabis Tax Grant FY 2022 funds, to fulfill Tier 1 screening requirements. The TOX Unit is requesting funds from CHP Cannabis Tax Grant FY 2023 to purchase an additional instrument to fulfill Tier 1 confirmatory testing guidelines. Both grants are needed to fulfill Tier 1 requirements: one grant (FY 2022) is for screening, while the other (FY 2023) is for confirmatory testing.

The TOX Unit is fully dedicated to meeting the NSC Tier 1 drug confirmation testing recommendations but lacks instruments with sufficient sensitivity and specificity. Currently, the TOX Unit meets all Tier 1 confirmatory testing guidelines for cannabinoids, central nervous system depressants, and central nervous system stimulants, but does not meet the recommendations for narcotic analgesics, confirming only six of the eleven recommended drugs. The LAPD is requesting funding through the CHP Cannabis Tax Grant FY 23-24 to purchase the new LC/MS/MS. This new instrument will offer several improvements over the TOX Unit's current technology, including greater sensitivity, reduced blood sample volume, and the ability to test for a broader range of drugs simultaneously with minimal sample preparation. The project will include purchasing a LC/MS/MS and validating a comprehensive method for Tier 1 narcotic analgesics that includes morphine, codeine, hydrocodone, oxycodone, methadone, and fentanyl (currently tested for in-house using a combination of GC/MS and LC/MS/MS methods). The TOX Unit will add the remaining Tier 1 narcotic analgesics, 6-monoacetylmorphine, buprenorphine, norbuprenorphine, tramadol, and o-desmethyltramadol (currently confirmed by subcontracting to outside laboratories), and the top five most relevant fentanyl analogs to this new method. With the new LC/MS/MS, the LAPD's TOX Unit will fully meet the NSC Tier 1 recommendations for drug confirmatory testing on every DUID blood specimen tested, offer more testing options to customers, and reduce the costs associated with subcontracted testing. The new instrument will also provide the sensitivity and specificity needed to accomplish projects beyond the scope of this grant such as testing for NSC Tier 2 drugs and future updates to national standards.



5. Problem Statement & Proposed Solution

First, clearly identify the problem/need (Problem Statement) in your local community that will be addressed by the Project. Then, clearly identify the Proposed Solution to address the problem/need. If applicable, provide recent and high-level statistical data that directly supports the problem/need in your local community. PLEASE DO NOT COPY AND PASTE TABLES IN FIELD - EITHER TYPE INFORMATION IN FIELD OR ATTACH DOCUMENT.

PROBLEM: The LAPD TOX Unit receives approximately 1,200 blood specimens per year for drug testing related to DUID. The TOX Unit's general testing procedure for DUID blood specimens involves two steps: first the blood specimen is screened for drugs of abuse; and second, positive drug screening results are confirmed by a second analytical technique using either a gas chromatograph with mass spectrometer (GC/MS) or a liquid chromatograph with tandem mass spectrometers (LC/MS/MS).

In 2017, the NSC Alcohol, Drug, and Impairment Division first published recommendations for toxicological investigation of drug-impaired driving, with an updated publication in June 2021 (1). Also, in 2021, the ASB published ASB Standard 120, "Standard for the Analytical Scope and Sensitivity of Forensic Toxicological Testing of Blood in Impaired Driving Investigations" (2). Both standards contained identical scopes and were created by experts in the field to standardize toxicology testing across the nation.

The TOX Unit is fully dedicated to meeting the NSC Tier 1 drug testing recommendations but lacks sufficient instrumentation with the sensitivity and specificity to meet these guidelines. The TOX Unit has six GC/MS instruments used for drug confirmatory testing. For decades, GC/MS technology was the gold-standard in toxicology testing and has many advantages including method robustness, relatively high precision, and good reproducibility. However, these instruments lack sensitivity and are incapable of distinguishing between multiple drugs simultaneously. Additionally, these instruments require compounds to be in the gas phase for analysis, and use a carrier gas, such as helium, for compound separation, which is becoming increasingly more expensive and difficult to obtain due to a world-wide helium shortage.

The TOX Unit has been able to compensate for GC/MS sensitivity issues by using a larger sample size for analysis. All GC/MS confirmatory methods require two milliliters of blood (per drug class) to achieve the appropriate reporting limits set by NSC testing recommendations. The typical blood specimen size received by the laboratory for each DUID investigation is ~ 8mL or less. Using a GC/MS for drug confirmations is adequate when confirmations are only needed for one or two drug classes, but becomes problematic when more testing is needed, due to the volume of blood needed to confirm each drug class. In the last five years, polydrug use has increased annually in DUID investigations, requiring the need for multiple analyses to be performed on the same sample to confirm each drug class. Since 2018, the laboratory has experienced a 29% yearly increase in the total number of polydrug blood specimens that screen positive for cannabinoids and at least one other drug. Given the large amount of blood needed for GC/MS confirmatory methods, it is not uncommon to deplete the blood specimen before completing all laboratory tests, which does not leave any sample available to the defense for independent testing. While GC/MS instrumentation in the past has been adequate for confirmatory testing, it is no longer able to meet current toxicology testing demands.

The majority of toxicology laboratories are upgrading equipment from GC/MS to LC/MS/MS technology to meet the sensitivity requirements of NSC Tier 1 drug testing guidelines. LC/MS/MS provides many advantages over GC/MS, including reduced sample volume, the elimination of expensive carrier gases, and the ability to analyze many compounds simultaneously. Although the TOX Unit currently has three LC/MS/MS instruments to use for DUID confirmatory testing, it is the goal of the TOX Unit to entirely phase out GC/MS for LC/MS/MS technology. The LC/MS/MS instruments in the TOX Unit consist of:

- A 14-year-old instrument nearing the end of its life expectancy,
- A LC/MS/MS currently used exclusively for cannabinoid confirmatory testing (which accounts for approximately 67% of the TOX Unit confirmatory testing), and
- One remaining LC/MS/MS used to fulfill all NSC testing guidelines for central nervous system depressants.

To phase out existing GC/MS(s), all confirmatory methods need to be transferred to the LC/MS/MS, a time-intensive process that includes method development and validation. Due to prioritization of casework, workload volume and requirements for timely analysis, scheduling method development and validation activities on current LC/MS/MS instruments has been challenging and led to a bottleneck at the LC/MS/MS(s) preventing timely additions to the TOX Unit testing scope.

For some low-concentration drugs that are not easily detected on the GC/MS, the TOX Unit has not had sufficient resources to validate an LC/MS/MS method for their detection. These drugs are currently subcontracted to outside laboratories. This is a substantial cost to the TOX Unit and requires prosecutors to subpoena these outside laboratory employees to testify to their report and interpretation. Approximately 1% of the TOX Unit's DUID specimens are sent to



a subcontracted laboratory for narcotic analgesic testing. The TOX Unit's narcotic analgesic testing needs to be fully moved to LC/MS/MS to achieve the NSC requirements for DUI samples. The current GC/MS method must be transferred to LC/MS/MS, and five new analytes must be added to the scope. This is critical as fentanyl has moved from the TOX Unit's #5 most prevalent drug to #4, and the percentage of DUI cases screening positive for fentanyl has increased by 64% since 2020. Similarly, oxycodone has moved up in prevalence, and methadone is now in the top 10 drugs confirmed. In addition, the national trend indicates that the prevalence of fentanyl analogues is rising. Adding fentanyl analogues to the TOX Unit's scope of testing will provide more comprehensive results to customers.

SOLUTION: The TOX Unit plans to purchase a liquid chromatograph with tandem mass spectrometers (LC/MS/MS) to meet the remaining NSC Tier 1 drug testing recommendations for narcotic analgesics. LC/MS/MS has many advantages including greater sensitivity (lower detection limits), higher accuracy, and the capability to analyze multiple compounds simultaneously. The new LC/MS/MS will allow the TOX Unit to fully meet NSC and ASB's published recommendations for drug confirmatory testing of narcotic analgesics, while also including the top five fentanyl analogs. This increase in sensitivity will reduce sample volumes needed for each confirmation method, which is imperative for DUI testing with polydrug use. In addition to fully meeting NSC testing recommendations, the new LC/MS/MS will allow the TOX Unit to upgrade and phase out existing equipment (GC/MS and older LC/MS/MS), create redundancy in LC/MS/MS instrumentation, and expedite the method development and validation processes. This project will also eliminate the need for expensive testing subcontracted to outside laboratories.

The new LC/MS/MS will allow the TOX Unit to expand future testing capabilities beyond the current grant cycle. With the dynamic drug scene and the increasing prevalence of novel psychoactive substances (NPS) found in toxicology casework nationwide, having sensitive instrumentation available is critical to keep up with these demands. By utilizing this technology, the TOX Unit will be able to streamline its workflow by combining existing smaller confirmatory methods into larger, comprehensive methods, which will in turn reduce the backlog, turnaround time, and sample volume required for testing. The new LC/MS/MS can eventually be used to confirm NSC Tier 2 drugs (currently recommended but not required for DUI blood specimens).

The substantial upfront cost of purchasing LC/MS/MS instruments has led to the continued use of less sensitive, outdated technology for DUI testing in many toxicology laboratories or relying on outside laboratories to perform the testing. Overcoming this cost barrier will allow the TOX Unit to make enormous strides in fully meeting NSC Tier 1 testing recommendations for this grant project and future projects.

Citations:

(1) D'Orazio, Amanda et al, Recommendations for Toxicological Investigation of Drug-Impaired Driving and Motor Vehicle Fatalities-2021 Update. *Journal of Analytical Toxicology*, 2021; 45: 529 – 536.

(2) ANSVASB. 2021. Standard 120, First Edition: Standard for the Analytical Scope and Sensitivity of Forensic Toxicological Testing of Blood in Impaired Driving Investigations [Internet]. [Cited 18 February 2022.] Available from <https://www.aafs.org/asb-standard/standard-analytical-scope-and-sensitivity-forensic-toxicological-testing-blood>.

Statistical Data/Report(s)



6. Performance Measures/Scope of Work

Using what you provided in the Project Description, detail the activities/items below which will serve as your goals and objectives for the Project. For each, include estimated timelines (ex: monthly, quarterly), quantitative measurements (ex: reduction of DU/DUID by %), and justification detailing how it will enhance/support the Project. NOTE: The Performance Measures/Scope of Work must be consistent with the Project Description and Budget. PLEASE DO NOT COPY AND PASTE TABLES IN FIELD - TYPE INFORMATION IN FIELD.

The LAPD TOX Unit goals for this project include:

[1] Full compliance with the NSC and ASB standards for confirmatory testing of DUID blood specimens for narcotic analgesics that includes morphine, codeine, hydrocodone, oxycodone, methadone, fentanyl, 6-monoacetylmorphine, buprenorphine, norbuprenorphine, tramadol, and o-desmethyltramadol.

[2] Include the top five most relevant fentanyl analogues in DUID confirmatory testing scope, at forensically relevant limits of detection.

[3] Reduce the amount of blood specimen used for narcotic analgesic confirmations (currently 2 mL for GC/MS methods).

[4] Eliminate the need for subcontracted testing to meet NSC and ASB standards for confirmatory testing for narcotic analgesics.

To achieve these goals, the LAPD TOX Unit is proposing to purchase and validate an ultra-high-performance liquid chromatograph with tandem mass spectrometers (LC/MS/MS) to streamline its current narcotic analgesic test method.

The proposed implementation timeline for the 24-month program is as follows:

- First Quarter:
 - o The LAPD Grants Section will obtain the Los Angeles City Council's resolution to enter into a grant contract for the CHP Cannabis Tax Fund Grant Program
- Second Quarter:
 - o The Forensic Science Division (FSD) and Grants Section will initiate the purchasing process with the City of Los Angeles and CHP Cannabis Tax Fund Grant Program guidelines.
- Third Quarter:
 - o The FSD and Grants Section will complete the purchasing process with the City of Los Angeles and CHP Cannabis Tax Fund Grant Program guidelines.
 - o The FSD will validate a comprehensive confirmation test method for all NSC Tier 1 drug testing recommendations for narcotic analgesics (morphine, codeine, hydrocodone, oxycodone, methadone, fentanyl, 6-monoacetylmorphine, buprenorphine, norbuprenorphine, tramadol, o-desmethyltramadol), and the top five relevant fentanyl analogs. Validation is expected to be completed within twelve weeks after instrument installation.
- Fourth Quarter:
 - o Continue validation of comprehensive confirmation test method for all NSC Tier 1 drug testing recommendations for narcotic analgesics and fentanyl analogs.
- Fifth Quarter:
 - o All FSD staff that use the current LC/MS/MS will be trained on the new instrument and the narcotic analgesic confirmation test method. Training is expected to be completed within three weeks.
- Sixth Quarter:
 - o Collect Data and Metrics
- Seventh Quarter:
 - o Collect Data and Metrics



- Eighth Quarter:
 - o Collect Data and Metrics

The program objectives should be met once the program activities are completed.



7. Project Performance Evaluation

Provide the method of evaluation to show Project effectiveness and positive impact(s) on the community. These strategies shall include captured quantitative/qualitative data and a communication plan to share Project results with both internal and external stakeholders. PLEASE DO NOT COPY AND PASTE TABLES IN FIELD - TYPE INFORMATION IN FIELD.

The LAPD's Forensic Science Division (FSD) uses a Laboratory Information Management System (LIMS) to track laboratory activities, chain of custody, services performed, personnel, and other statistical information throughout the entire laboratory. LIMS data is stored on the LAPD's local area network, routinely checked for integrity, and backed up daily. LIMS reports will be used to collect data to support the following performance measures and will be reported to CHP Cannabis Tax Grant Program personnel.

The FSD will work with the LAPD Grants Section to track and report the following:

- (1) Date the Los Angeles City Council approves the spending of funds received for this grant project.
- (2) Date the purchase order (P/O) is submitted to the vendor for the LC/MS/MS.
- (3) Date of installation of LC/MS/MS.
- (4) Date of the start and end of the method validation for comprehensive narcotic analgesic confirmation method.
- (5) Date new instrument and narcotic analgesic confirmation methods are released for use on forensic DUID casework.
- (6) Number of narcotic analgesic confirmation tests completed per month with the new confirmation method.
- (7) Average turn-around time on narcotic analgesic confirmations completed per month with the new confirmation method.

The FSD will provide a summary of the new confirmation test method to the Grant Coordinator to include the following parameters:

- (1) Scope of confirmation (e.g. morphine, codeine, hydrocodone, oxycodone, methadone, fentanyl, 6-monoacetylmorphine, buprenorphine, norbuprenorphine, tramadol, and o-desmethyltramadol).
- (2) Limits of quantitation (for all drugs listed above).
- (3) Percent compliance with NSC's list of narcotic analgesics.
- (4) Number of fentanyl analogs added to scope of testing.
- (5) Sample laboratory report.



8. Program Sustainability

Describe the plan for reducing reliance on future grant funding. Include a summary and timeframe to continue efforts when grant funds are either not available or significantly reduced. PLEASE DO NOT COPY AND PASTE TABLES IN FIELD - TYPE INFORMATION IN FIELD.

The LAPD will assume responsibility of the personnel, supplies, and service maintenance that the program will need after the grant performance period.

It is anticipated that all major components of the LC/MS/MS will come with a three-year warranty. Once the warranty has expired, the LAPD will assume maintenance costs and add the instruments to the laboratory's general service contract. The TOX Unit procures and maintains service contracts for all instruments as a regular course of business and will include the new LC/MS/MS. Service contracts include annual planned/preventative maintenance and any repairs required to maintain the instruments in proper working condition. The TOX Unit will take responsibility for purchasing all consumable supplies required to sustain the program for the life of the instrument. Consumable supplies include solvents, analytical gas (i.e. argon), autosampler vials, pipette tips, and glassware.



9. Administrative Support

Describe the administrative support, including the Organization/Agency's grant experience, personnel, and physical resources needed to successfully implement the Project. PLEASE DO NOT COPY AND PASTE TABLES IN FIELD - TYPE INFORMATION IN FIELD.

The Forensic Science Division (FSD) is a full-service crime laboratory accredited by the American National Standards Institute – American Society for Quality National Accreditation Board (ANAB) to the International Organization of Standardization – International Electrotechnical Commission's 17025 standard. In March 2019, the FSD was assessed for re-accreditation through March 23, 2023. The FSD has a full-service Toxicology (TOX) Unit that performs drug screening and confirmation testing, blood alcohol testing, and breath-alcohol instrument calibration and maintenance. The TOX Unit personnel also testify as expert witnesses in court proceedings to the effects of alcohol and drugs on driving performance and in drug-facilitated sexual assault cases. The TOX Unit's workload consists almost entirely of blood specimens associated with driving under the influence of alcohol and/or drugs (DUI/DUID) crimes and misdemeanors. The TOX Unit receives a yearly average of 2,000 blood specimens, 94% of which are DUI and/or DUID-related. Since 2017, the TOX Unit has validated several test methods to confirm designer benzodiazepines, zolpidem, carisoprodol, fentanyl, methadone, and cocaethylene in blood specimens.

In February 2023, using funding from the CHP Cannabis Tax Fund Grant FY 2021-2022, the TOX Unit successfully completed a validation project and implemented a confirmation method on the Thermo Altis LC/MS/MS to confirm THC, OH-THC, and Carboxy-THC in blood specimens.

The TOX Unit is fully staffed with 15 personnel: two Supervising Criminalists, two Criminalist IIIs (Technical Leads), nine Criminalist IIs, one Criminalist I, and one Laboratory Technician. The Unit has two instrument specialists, one with 15 years of experience, and one with 10 years of experience in developing and validating methods on both the UHPLC/MS/MS and ultra-high-performance liquid chromatography/high resolution mass spectrometry. For this grant, the TOX Unit has the technical staff required to complete and sustain the program long-term.

The proposed program will be staffed with a program manager, assistant program manager, and a grant analyst. The Program Manager, Kristina Takeshita, has been a Criminalist with the LAPD's FSD for 27 years, with 14 years of experience in a supervisory position managing technical staff and various FSD projects, including grant management. The assistant Program Manager, Dr. Katheryn Sanchez, has been a Criminalist with the LAPD's FSD for 8 years, with 10 years of experience managing technical staff and projects, including grant-funded projects with the LAPD and graduate school. During this time, she has coordinated numerous validations for drug confirmation test methods using the gas chromatograph with mass spectrometer (GC/MS) and liquid chromatograph with tandem mass spectrometers (LS/MS/MS). An LAPD Grant Analyst will be assigned to the proposed program to submit all financial and progress reports as well as manage all grant administration duties.

The LAPD has several years of experience in managing federal grants. It has been awarded and has successfully managed grants ranging from \$100,00 to \$16,000,000 from various local, state, and federal entities including FEMA and DOJ. The LAPD Grants Section consists of a Grants Manager and six Grant Analysts to oversee and report on over 30 active grants. The FSD has also demonstrated the ability to successfully implement federal grant programs with its DNA Capacity Enhancement and Backlog Reduction Program (2009 – 2020), the Coverdell Competitive Grant (2008, 2010, 2014, and 2019), and the CHP Cannabis Tax Fund Grant for FY 2021-22 and FY 2022-23.



10. Other Grant Programs

Impaired Driving Enforcement Funding

Has your Organization/Agency previously received grant funding for impaired driving enforcement?

- Yes
 No

If yes, detail the outcome. PLEASE DO NOT COPY AND PASTE TABLES IN FIELD - TYPE INFORMATION IN FIELD.

The Department has received grant funds from the California Office of Traffic Safety (OTS) for over 20 years to fund DUI and traffic enforcement operations. The OTS grant funding for DUI enforcement has been an integral part of the Department's overall DUI enforcement plan. In 2022, the Selective Traffic Enforcement Program (STEP) Grant funded 167 DUI checkpoints, which resulted in the following:

- 278,349 Vehicles Through the Checkpoints
- 126,009 Drivers Screened
- 872 SFSTs Performed
- 349 Drivers Arrested for DUI
- 171 Drivers Arrested for DUID
- 20 Drivers Arrested for Combination DU/DUID

In addition to the checkpoints, the STEP Grant funded 154 DUI saturation patrols, which resulted in the following:

- 1,835 Traffic Stops
- 370 SFSTs Performed
- 207 Drivers Arrested for DUI
- 55 Drivers Arrested for DUID
- 15 Drivers Arrested for Combination DU/DUID

Proposal to Other Grant Programs

Has or will your Organization/Agency submit a proposal to another grant program for this Project (ex: funds for the same components as this Project, or for similar/related components that will be completed during the same time period as this Project)?

- Yes
 No

If yes, identify the granting Organization/Agency(s), grant program name(s), proposal title, date submitted (or to be submitted), and relationship between the proposals. In addition, clearly distinguish which tasks would be funded by CGU and which tasks would be funded by other Organizations/Agencies. PLEASE DO NOT COPY AND PASTE TABLES IN FIELD - TYPE INFORMATION IN FIELD.



11. Terms and Conditions

By submitting your Grant Application, you agree to the following Terms and Conditions:

I certify, under penalty of perjury, that the information I entered in this Grant Application is true and complete to the best of my knowledge. I further understand that any false, incomplete, or incorrect statements may result in my disqualification from the grant process or dismissal from receiving grants funded by the California Highway Patrol (CHP), Cannabis Tax Fund Grant Program. I authorize the California Highway Patrol, Cannabis Grants Unit (CGU), to investigate referenced documents or other documents submitted to the program to check the accuracy of the information provided.

I agree with the Request for Application, the above Terms and Conditions, and the California Code of Regulations, Title 13, Division 2, Chapter 13, Sections 1890.00 through 1890.27.

I Agree

When using the GMS (AmpliFund), I authorize the state to take my requested action by an electronic means and authorize the state to accept the combination of my User ID and password in lieu of my written signature.

I Agree

My password is unique to me and is to remain confidential. I will not allow other individuals to use my User ID and password to access the GMS (AmpliFund).

I Agree

It is my responsibility to maintain the confidentiality of GMS (AmpliFund) information.

I Agree

Once I submit the Grant Application, I am unable to add, edit, or delete any Grant Application information.

I Agree

Confidentiality Notice: All documents submitted as a part of the Cannabis Tax Fund Grant Program Grant Application are public documents and may be subject to a request pursuant to the California Public Records Act. The CHP, CGU, cannot ensure the confidentiality of any information submitted in or with this Grant Application (Gov. Code, § 6250 et seq.).

I Agree

Generated Income Disclaimer: There will be no program income generated from this grant. Nothing in this Grant Agreement shall be interpreted as a requirement, formal or informal, that a particular law enforcement officer issue a specified or predetermined number of citations in pursuance of the goals and objectives. Although special emphasis will be placed upon violations specific to this Grant Agreement, appropriate enforcement action will be taken for all observed violations.

I Agree

Financial Information System for California Government Agency Taxpayer ID (FI\$Cal Form)

A FI\$Cal Form is required for reimbursement. If the Grant Applicant does not have a completed FI\$Cal Form at final Grant Application submission time, the Grant Applicant may submit the completed FI\$Cal Form via email to CGU prior to execution of the Grant Agreement. NOTE: The "Remit-To Address" on the FI\$Cal Form MUST match the "Official Address to Receive Reimbursement Payment" you entered in Form #1, Organization/Agency Representative. This address shall be the official address on file with FI\$Cal and the State Controller's Office (SCO) to receive warrants (Reimbursement Request Payments). Forms are located on the Cannabis Tax Fund Grant Program's web site at <https://www.chp.ca.gov/programs-services/programs/cannabis-tax-fund-grant-program>.

I Agree

FI\$Cal Form

LAPD FI\$Cal.pdf

City Council or County Resolution

A county, city, district, or other public body shall provide a copy of a resolution, order, motion, or ordinance of local governing body, which by law has the authority to enter into an agreement authorizing execution of a Grant Agreement. If the Grant Applicant does not have a signed resolution at final Grant Application submission time, the Grant Applicant may submit a signed resolution via email to CGU prior to execution of the Grant Agreement. NOTE: The resolution MUST explicitly state the Organization/Agency has delegated authority to enter into a Grant Agreement for the requested amount.



I Agree

Resolution



Budget

Proposed Budget Summary

Expense Budget

	Grant Funded	Total Budgeted
Personnel		
Civilian Overtime for Validation	\$10,000.00	\$10,000.00
Subtotal	\$10,000.00	\$10,000.00
Equipment		
Liquid Chromatograph with Tandem Mass Spectrometers (LC/MS/MS)	\$690,000.00	\$690,000.00
Subtotal	\$690,000.00	\$690,000.00
Total Proposed Cost	\$700,000.00	\$700,000.00

Revenue Budget

	Grant Funded	Total Budgeted
Grant Funding		
Award Requested	\$700,000.00	\$700,000.00
Subtotal	\$700,000.00	\$700,000.00
Total Proposed Revenue	\$700,000.00	\$700,000.00

Proposed Budget Detail

See attached spreadsheet.

Proposed Budget Narrative

Personnel

Costs may include compensation for salaries and fringe benefits, such as annual leave and sick leave, for work directly related to the Project. Personnel salaries must be consistent with Project activities. To be eligible for reimbursement, Personnel Services must occur within the Project Performance Period. Please itemize separate Budget Line Items. Please include salary and benefits, combined/rolled-up, in the same Budget Line Item. For EACH Budget Line Item, the narrative shall include the below: * Job Title/Classification(s) * Description of Work/Job Duties * Number of Hours for Each Classification

Civilian Overtime for Validation

The LAPD TOX Unit is requesting \$10,000 for overtime to validate the new narcotic analgesic confirmation method in a timeframe that is comparable with the performance period of this grant program. The average hourly pay of a Criminalist is \$64 per hour. The LAPD overtime rate is 1.5 times hourly pay and overtime benefits is 6.26% for civilian personnel. The average overtime rate with benefits is \$102.04 per hour. It is estimated that 98 hours will be used for this purpose. 98 hours x \$102.04/hour = \$10,000.



Equipment

Costs may include non-expendable, tangible, personal property having a normal useful life of more than one year, and an acquisition cost of at least \$5,000 (ex: four identical assets, which cost \$1,250 each, for a total of \$5,000, are not considered an equipment purchase). Grant funds should be used to upgrade or purchase forensic laboratory equipment that improves data collection and/or laboratory testing capabilities. Equipment shall be directly related and necessary to complete grant-funded activities included in the Project. Equipment should be purchased at the beginning of the Project Performance Period to ensure it is utilized when completing corresponding Project activities. To be eligible for reimbursement, Equipment must be purchased and received within the Project Performance Period. Please itemize separate Budget Line Items for each Equipment. For EACH Budget Line Item, the narrative shall include the below: * Description of Equipment * Quantity * Unit Cost and Total Cost

Liquid Chromatograph with Tandem Mass Spectrometers (LC/MS/MS)

The Los Angeles Police Department's (LAPD) Toxicology (TOX) Unit will purchase one new generation ultra-high-performance liquid chromatograph with tandem mass spectrometers (LC/MS/MS) with the sensitivity requirements to fully meet National Safety Council (NSC) Tier 1 drug testing recommendations. The LAPD is seeking \$690,000 to cover the cost of the instrument and associated equipment, tax, shipping/handling, and installation. The new LC/MS/MS is a sensitive, selective instrument capable of quantitation and characterization of drugs in blood specimens collected from Driving Under the Influence of Drugs (DUID) investigations. The LC/MS/MS is an ideal instrument for confirming a wide range of drugs in complex matrices such as blood and urine with very low limits of detection. The instrument is needed to create and validate a comprehensive narcotic analgesic confirmation panel for DUID-related blood specimens that meet the NSC and American Academy of Forensic Science Standards Board (ASB) published standards. Additionally, the instrument can be used for projects beyond this grant cycle to address regional drug trends, changes in national testing guidelines, and fulfilling Tier 2 DUID drug testing recommendations (suggested but not required). The TOX Unit has the staff and technical expertise required to complete this project but lack sufficient instrumentation with the sensitivity requirements of the NSC standards. The ideal instrument comes with the following components: (1) LC/MS/MS with heated IonSpray probe (2) Multi-year warranty protection plan (3) Nitrogen generator (4) Personal Computer with LC/MS/MS operating software (5) All sub-components needed for installation (6) Installation